Table 3.

Clinical Characteristics of Patients With Objective Responses

Age, y/Sex	Baseline LDH	No. of Prior Therapies	Disease Sites	Best Response	Time to Response, mo	Response Duration, mo	OS, mo
76/Man	113	3	Lung, soft tissue	irCRa	3.5	10.2+	13.7+
78/Woman	160	3	Lung, soft tissue, bone	irPR	2.4	2.8	8.3
62/Man	92	4	Soft tissue	irCRb	5.2	6.2+	11.4+
66/Man	121	2	Lung, soft tissue, lymph node	irCR	5.6	5.6+	11.2+
62/Man	171	3	Lung, lymph node	irPR	4.3	6+	10.3+
47/Man	210	1	Lymph node	irCRc	2.6	4.4+	7.0+

LDH indicates lactate dehydrogenase; OS, overall survival; irCR, immune-related complete response; irPR, immune-related partial response.

^aThis patient experienced a complete response to ipilimumab and surgery.

^bThis patient received radiotherapy prior to study entry.

^cThis patient was found to have achieved a pathologic complete response when the only metastatic site was resected.